Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Table 1 Baseline demographic and clinical characteristics of the patients

Variables	Total (n = 102)
Age, mean ± SD (range), yr	57.64 ± 10.37 (34-91)
Male, n (%)	89 (87.25)
ECOG PS, n (%)
0	53 (51.96)
1	49 (48.04)
Etiology, HBV/others, n (%)	80/22 (78.43/21.57)
BCLC stage, B/C, n (%)	48/54 (47.06/52.94)
Maximum tumor diameter, mean ± SD, cm	6.80 ± 3.74
Number of tumors > 3, n (%)	51 (50.00)
Portal vein invasion, n (%)
Yes	29 (28.43)
Extrahepatic metastasis, n (%)
Yes	42 (41.18)
Extrahepatic metastatic sites, n (%)
Lung	27 (26.47)
Bone	7 (6.86)
Lymph nodes	13 (12.75)
Abdominal cavity	7 (6.86)
PD-1 antibody class, n (%)
Sintilimab	52 (50.98)
Nivolumab	20 (19.61)
Camrelizumab	17 (16.67)
Pembrolizumab	7 (6.86)
Toripalimab	6 (5.88)
Child-Pugh class, n (%)
A	93 (91.18)
B	9 (8.82)
AFP level, n (%)
> 400 ng/mL	49 (48.04)
≤ 400 ng/mL	53 (51.96)
DCP level, n (%)
> 40 mAU/mL	89 (87.25)
≤ 40 mAU/mL	13 (12.75)
NLR, mean ± SD	2.46 ± 1.59
LDH, mean ± SD, U/L	198.52 ± 102.05

AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer Classification; DCP: Des-gamma-carboxyprothrombin; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HBV: Hepatitis B virus; LDH: Lactate dehydrogenase; NLR: Neutrophil lymphocyte ratio; PD-1: Programmed cell death protein-1.